8-K: SpringWorks Therapeutics' GOMEKLI Receives FDA Approval for NF1-PN Treatment

SpringWorks Therapeutics' GOMEKLI (mirdametinib) has been approved by the FDA for treating adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

Summary

• The FDA has approved SpringWorks Therapeutics' GOMEKLI (mirdametinib) for the treatment of adult and pediatric patients (2 years and older) with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed surgically.
• NF1 is a genetic disorder affecting approximately 100,000 individuals in the U.S., with a 30-50% lifetime risk of developing PNs.
• GOMEKLI demonstrated a 41% objective response rate (ORR) in adults and a 52% ORR in children in the Phase 2b ReNeu trial.
• The median best percentage change in target PN volume was -41% in adults and -42% in children.
• The wholesale acquisition cost for GOMEKLI is set at $206.25 per mg, with estimated average treatment costs of $22,000 per month for pediatric patients and $30,000 per month for adult patients.
• SpringWorks has assembled a U.S. commercial field organization of 35 territory business managers plus regional business directors to support the commercialization of GOMEKLI.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA approval of GOMEKLI, which addresses a significant unmet need in the treatment of NF1-PN. The clinical trial results are promising, and management expresses optimism about the drug's potential. However, there are some risks and potential side effects associated with the treatment.

Positives

• GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN.
• The Phase 2b ReNeu trial demonstrated robust ORR and deep, durable reductions in tumor volume.
• Patients experienced early and sustained improvements in pain and quality of life.
• GOMEKLI has a manageable safety and tolerability profile.
• SpringWorks has a comprehensive patient support program called SpringWorks CareConnections.

Negatives

• GOMEKLI can cause ocular toxicity, including retinal vein occlusion and blurred vision.
• GOMEKLI can cause left ventricular dysfunction.
• Dermatologic adverse reactions, including rash, are common with GOMEKLI treatment.
• GOMEKLI can cause fetal harm when administered to a pregnant woman.

Risks

• The success of SpringWorks' commercialization efforts for GOMEKLI is uncertain.
• SpringWorks has limited experience as a commercial company.
• Obtaining and maintaining adequate coverage and reimbursement for GOMEKLI may be challenging.
• Clinical trial data may not be predictive of final results or the results of other studies.
• Regulatory authorities may require additional information or further studies.

Future Outlook

SpringWorks anticipates GOMEKLI will be available in the U.S. within two weeks through a specialty pharmacy and distributor network, and the European Commission is expected to make a decision on the Marketing Authorization Application in 2025.

Management Comments

• Saqib Islam, Chief Executive Officer of SpringWorks, stated that the company is honored to serve both adults and children with NF1-PN and provide them with a therapy that has the potential to shrink their tumors and offer meaningful symptomatic relief.
• Christopher Moertel, M.D., lead investigator of the ReNeu trial, noted that the approval represents an important advance, especially for adults who previously did not have an approved treatment.

Industry Context

This approval positions SpringWorks as a key player in the rare disease and oncology space, particularly in the treatment of NF1-PN, where there was a significant unmet need. The approval also highlights the importance of collaboration between industry, researchers, and patient advocacy groups in advancing innovative science.

Comparison to Industry Standards

• Prior to GOMEKLI's approval, there were limited treatment options available for NF1-PN, particularly for adults.
• Selumetinib (Koselugo) is another MEK inhibitor approved for pediatric patients with NF1-PN, but GOMEKLI is the first to be approved for both adults and children.
• The objective response rates observed in the ReNeu trial (41% in adults, 52% in children) compare favorably to historical data and other treatments for NF1-PN.

Stakeholder Impact

• Patients with NF1-PN now have a new treatment option that can potentially shrink tumors and provide symptomatic relief.
• Healthcare providers have a new tool to manage NF1-PN in both adult and pediatric patients.
• SpringWorks Therapeutics benefits from the FDA approval and the potential commercial success of GOMEKLI.
• The FDA's approval process and priority review voucher program are highlighted as mechanisms to encourage the development of treatments for rare diseases.

Next Steps

• SpringWorks will make GOMEKLI available in the U.S. within two weeks through a specialty pharmacy and distributor network.
• The European Commission is expected to make a decision on the Marketing Authorization Application for mirdametinib in 2025.

Key Dates